The Board approved AFR for Qtr/year ended 31 March 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Brawn Biotech Ltd's Board has approved the audited financial results for Q4 FY25 and the full year ended 31 March 2025. Revenue from operations fell sharply to Rs. 1,538.05 lakhs in FY25 from Rs. 3,558.90 lakhs in FY24, a drop of nearly 57%. The company reported a net loss of Rs. 178.07 lakhs for FY25, slightly narrower than the Rs. 184.42 lakhs loss in FY24, with Q4 FY25 alone showing a loss of Rs. 63.88 lakhs. Total equity eroded to Rs. 336.23 lakhs (from Rs. 506.50 lakhs), while total liabilities rose to Rs. 1,712.57 lakhs, pushing the debt-to-equity ratio above 5x. Cash flow from operations turned negative at Rs. (79.41) lakhs versus a positive Rs. 222.08 lakhs last year.
Continuing losses, a steep revenue decline, negative operating cash flow, and a very high debt-to-equity ratio point to significant financial stress. Shareholders should view this as a negative development, with risks to solvency and going-concern status if performance does not improve.